ARCHIVES

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy

November 30, 2012

NIDDK Funds Trial On treatment Of Chronic Hepatitis C

August 13, 1999

NCI exceeds employment ceilings, must cut personnel in FY 2004, NIH says. Further cuts expected in extramural grant support staff.

January 30, 2004

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

NCI Programs: Institute Funds 24 DNA Microarray Centers

September 24, 1999

Gore, Agency Report, Support Legislation To Protect Genetic Info

January 30, 1998